MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Beam Therapeutics Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

19.88 0.96

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

19.3

Max

20.16

Pagrindiniai rodikliai

By Trading Economics

Pajamos

6.3M

-90M

Pardavimai

16M

30M

Pelnas, tenkantis vienai akcijai

-1.09

Pelno marža

-300.509

Darbuotojai

483

EBITDA

16M

-85M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+128.13% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-05-06

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-715M

1.8B

Ankstesnė atidarymo kaina

18.92

Ankstesnė uždarymo kaina

19.88

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bullish Evidence

Beam Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2024-09-26 14:20; UTC

Įsigijimai, susijungimai, perėmimai

Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit. -- IBD

Akcijų palyginimas

Kainos pokytis

Beam Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

128.13% į viršų

12 mėnesių prognozė

Vidutinis 45.33 USD  128.13%

Aukščiausias 80 USD

Žemiausias 20 USD

Remiantis 15 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Beam Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

15 ratings

12

Pirkti

3

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

16.98 / 20.809Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bullish Evidence

Vidutinės trukmės periodas

Very Strong Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.